SCHEMBL472833

SCHEMBL472833

Cc1nc(Cl)oc1-c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
NR1H4 Q96RI1 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
HPGD P15428 3/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
POLB P06746 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
NFKB1 P19838 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472566 0.85 NPC1 (0.37) KDM4EALDH1A1LMNAMEN1KMT2A
SCHEMBL472491 0.85 NPC1 (0.42) MEN1KMT2ARAB9ANPC1TSHR
SCHEMBL5546174 0.84 CCR9 (0.44) KDM4EALDH1A1LMNANR1H4MEN1
SCHEMBL472454 0.82 NOTUM (0.38) KDM4EALDH1A1LMNANR1H4NOTUM
SCHEMBL472847 0.82 NPC1 (0.45) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL15088428 0.81 KDM4E (0.39) KDM4EALDH1A1LMNANR1H4MEN1
SCHEMBL472497 0.80 GAA (0.45) KDM4EALDH1A1GAANOTUM
SCHEMBL472556 0.80 MAPT (0.41) LMNANR1H4MEN1KMT2AMAPT
SCHEMBL472472 0.79 AHR (0.45) KDM4EALDH1A1RAB9ANPC1HSD17B10
SCHEMBL11750368 0.78 NR1H4 (0.46) KDM4EALDH1A1LMNANR1H4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2412372-A1 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases Abbott Laboratories (US) 2012-02-01 EP disclosed
US-7998993-B2 TRPV1 antagonists ABBOTT LABORATORIES (US) 2011-08-16 US disclosed
EP-2220059-B1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LAB (US) 2011-08-03 EP disclosed
EP-2220059-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2010-08-25 EP disclosed
US-20090124666-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2009-05-14 US disclosed
WO-2009055749-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124666-A1 TRPV1 ANTAGONISTS TRPV1, TRPV2, TRPV3 KDM4E 3900/4885ALDH1A1 2031/4885LMNA 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.